Dual Eligibles with Mental Disorders and Medicare Part D: How are They Slide Presentation from the AHRQ 2009 Annual ConferencSlide presentation from the AHRQ 2009 conference. Slide Presentation from the AHRQ 2009 Annual ConferenceOn September 16, 2009, Sam Zuvekas made this presentation at the 2009 Annual Conference. Select to access the PowerPoint® presentation (851 KB) (Plugin Software Help).Slide 1Dual Eligibles with Mental Disorders and Medicare Part D: How are They Faring?Julie DonohueUniversity of PittsburghHaiden HuskampHarvard Medical SchoolSam ZuvekasAgency for Healthcare Research and Quality Slide 2Context6 million Medicare beneficiaries dually eligible for Medicaid moved to Medicare Part D drug plans.Random assignment to one of multiple benchmark plans, can switchEstimated 60% of disabled and 20% of elderly dual-eligibles have mental disordersProtections "All or substantially all" rule for antidepressants, antipsychotics, and anticonvulsantsFixed copay for generics, slightly higher for branded drugs, can't use cost-sharing tiersRisk adjusted payments to PDPs Slide 3Medication Use and Spending: U.S. Community Population % With UseTotal Spending $Percent Distribution of Spending by SourceOOPMedicareMedicaidPrivateOther2005 Antidepressants (all)8.513.3b36214436Antipsychotics (all)1.35.5b23155146Anticonvulsants2.75.5b29233307ALL PRESCRIPTION DRUGS63.1213b393143772006 Antidepressants (all)8.413.2b3516*8*36*5Antipsychotics (all)1.35.7b2621*26*207Anticonvulsants2.85.7b3416*19*265ALL PRESCRIPTION DRUGS62.6224b35*20*7*33*6*SOURCE: Medical Expenditure Panel Survey 2005-2006 Slide 4Medication Use and Spending: Medicare Community Population % With UseTotal Spending $Percent Distribution of Spending by SourceOOPMedicareMedicaidPrivateOther2005 Antidepressants (all)16.03.8b418182310Antipsychotics (all)3.32.1b2546443Anticonvulsants7.02.1b29435229ALL PRESCRIPTION DRUGS91.088.5b4371623112006 Antidepressants (all)18.1*4.1b32*52*1*10*5Antipsychotics (all)3.61.9b2261*6*47Anticonvulsants7.21.9b3148*2*127ALL PRESCRIPTION DRUGS91.296.3b31*45*7*14*8*SOURCE: Medical Expenditure Panel Survey 2005-2006 Slide 5Medication Use and Spending: Dual Eligible Community Population % With UseTotal Spending $Percent Distribution of Spending by SourceOOPMedicareMedicaidPrivateOther2005 Antidepressants (all)18.80.9b2057032Antipsychotics (all)8.51.5b1228401Anticonvulsants13.00.9b1538210ALL PRESCRIPTION DRUGS88.018.7b19573122006 Antidepressants (all)20.81.0b9*84*5*03Antipsychotics (all)8.41.0b683*11*00Anticonvulsants11.50.6b*1278*7*12ALL PRESCRIPTION DRUGS87.017.7b1777*5*0*1SOURCE: Medical Expenditure Panel Survey 2005-2006 Slide 6Formulary Coverage of Selected Atypical AntipsychoticsDrug Product % Covered (Yes/No) '06'07'08Abilify100%100%100%Abilify DiscmeltN/A83%100%Risperdal100%100%100%Risperdal Consta (IM)93%100%100%Risperdal M-TAB ODT93%100%100%Zyprexa100%100%100%Zyprexa IM74%90%100%Zyprexa Zydis84%100%100%SOURCE: January 2006, 2007, and 2008 CMS Prescription Drug Formulary and Pharmacy Network Files Slide 7Formulary Coverage of Selected AntidepressantsDrug Product % Covered (Yes/No) '06'07'08Celexa17%29%28%Citalopram100%100%100%Lexapro71%83%88%Cymbalta100%100%100%Paroxetine100%100%100%Paxil 17%29%28%Paxil CR64%59%52%SOURCE: January 2006, 2007, and 2008 CMS Prescription Drug Formulary and Pharmacy Network Files Slide 8Use of Utilization Management Tools for Selected Atypical AntipsychoticsOf Plans that Cover Drug, % that Require Each Utilization Management ToolDrug ProductPrior AuthorizationStep Therapy '06'07'08'06'07'08Abilify14%14%12%0%5%7%Abilify DiscmeltN/A16%18%N/A5%7%Risperdal11%0%0%0.5%0%0%Risperdal Consta (IM)26%17%15%0.5%0%0%Risperdal M-TAB ODT11%6%6%0.5%0%0%Zyprexa11%10%7%0.5%3%7%Zyprexa IM23%16%7%0.5%4%7%Zyprexa Zydis7%19%18%0.5%0.2%2%SOURCE: January 2006, 2007, and 2008 CMS Prescription Drug Formulary and Pharmacy Network Files Slide 9Use of Utilization Management Tools for Selected AntidepressantsDrug ProductPrior AuthorizationStep Therapy '06'07'08'06'07'08Celexa0%2%2%0%3%51%Citalopram0%0%0%1%0%0%Lexapro0%0%0%0%14%26%Cymbalta15%1%2%0%24%33%Paroxetine0%0%0%4%0%0%Paxil0%2%2%0%3%51%Paxil CR5%0%1%5%7%39%SOURCE: January 2006, 2007, and 2008 CMS Prescription Drug Formulary and Pharmacy Network Files Slide 10Percentage of Benchmark PDPs Requiring Either Step Therapy or Prior Authorization for Any Drug2006Anticonvulsants: 31.8%Antidepressants: 25.4%Antipsychotics: 39.1%2007Anticonvulsants: 52.0%Antidepressants: 41.43%Antipsychotics: 37.7%2008Anticonvulsants: 62.2%Antidepressants: 50.1%Antipsychotics: 43.8%SOURCE: January 2006, 2007, and 2008 CMS Prescription Drug Formulary and Pharmacy Network Files Slide 11Other Findings from the LiteratureMedication Discontinuities Some evidence of problems accessing particular medications (Hall et al 2007; West 2007, 2009)Psychotropic Drug Prices Frank and Newhouse (2008) some evidence that prices for antipsychotics increased under Part DPlan Choice Most Dual Eligibles assigned randomly, few switch plans (11% in 2006, Neuman et al. 2007)Reduction in the Number of Benchmark Plans 409 plans in 2006 ≥308 in 20092009 Six states have ≤5 plans, Nevada has 1 Slide 12Summary and Implications: Out-of-Pocket CostsMajor Change in Financing of Psychotropic Medications: Out of pocket costs decreased for non dual-eligiblesOut of pocket costs flat for dual-eligiblesSome indirect evidence of medication discontinuities Slide 13Summary and Implications: Formulary CoverageFormulary coverage relatively generous But gaps for some formulationsIncreasing use of utilization management Consider monitoring prior authorization approval rates, include in plan performanceConsider alternatives to random assignment Slide 14Summary and Implications:PDP MarketPDPs exiting from market Limits choiceReassignment may lead to medication discontinuitiesDoubling of PDP risk corridors in 2008 exposes plans to greater risk and may lead to further plan exits if risk adjustment doesn't accurately reflect dual eligibles expected costs Consider changes in risk adjustment systems to include drug utilizationConsider exposing PDPs to less risk for dual-eligibles Slide 15More InformationDonohue, Julie M, Haiden A. Huskamp and Samuel H. Zuvekas. 2009. "Dual Eligibles with Mental Disorders and Medicare Part D: How Are They Faring?" Health Affairs 28(May/June): 746-759. Current as of December 2009 Internet Citation: Dual Eligibles with Mental Disorders and Medicare Part D: How are They: Slide Presentation from the AHRQ 2009 Annual Conferenc. December 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/news/events/conference/2009/zuvekas/index.html